-
公开(公告)号：EP4132932A1
公开(公告)日：2023-02-15
申请号：EP21783895.2
申请日：2021-04-07
IPC分类号： C07D487/10 , C07D471/10 , A61P35/02
-
公开(公告)号：EP3791185A1
公开(公告)日：2021-03-17
申请号：EP19725537.5
申请日：2019-05-07
发明人： ORDENTLICH, Peter , WANG, Lei , SANKOH, Serap , MEYERS, Michael
IPC分类号： G01N33/569 , G01N33/574
-
3.发明公开COMBINATION OF ER + LIGANDS AND HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF CANCER 审中-公开ER +配体和组蛋白去乙酰化酶抑制剂对癌症疗法相结合
公开(公告)号：EP2099443A1
公开(公告)日：2009-09-16
申请号：EP07854611.6
申请日：2007-11-09
IPC分类号： A61K31/165 , A61K31/44 , A61K31/335 , A61P35/00
CPC分类号： A61K31/165 , A61K31/335 , A61K31/44 , A61K45/06 , A61K2300/00
摘要： The present embodiments relate to compositions and methods of treatment of cancer. More particularly, the present embodiments relate to the combination of an ERα+ ligand with an HDACi for the treatment of cancer, methods of treating cancer and pharmaceutical compositions for treating cancer.
-
公开(公告)号：EP4073100A1
公开(公告)日：2022-10-19
申请号：EP20899869.0
申请日：2020-12-09
IPC分类号： C07K14/71 , C07K16/28 , A61P37/06 , A61K39/395
-
公开(公告)号：EP3624848A1
公开(公告)日：2020-03-25
申请号：EP18733390.1
申请日：2018-05-18
发明人： ORDENTLICH, Peter , WANG, Lei
IPC分类号： A61K39/395 , A61K31/4406 , C07K16/28 , A61P35/00
-
公开(公告)号：EP4337329A1
公开(公告)日：2024-03-20
申请号：EP22808351.5
申请日：2022-05-12
IPC分类号： A61P35/00 , A61P35/02 , A61K31/555 , A61K31/551
-
公开(公告)号：EP3345002A1
公开(公告)日：2018-07-11
申请号：EP16843146.8
申请日：2016-09-02
发明人： ORDENTLICH, Peter
IPC分类号： G01N33/574 , G01N33/487 , C07C223/06 , C12N5/0786
CPC分类号： G01N33/57492 , A61K31/00 , A61K31/4406 , A61K31/5685 , A61K39/3955 , C07K16/2827 , C07K2317/24 , G01N33/5091 , G01N33/56972 , G01N2800/52
摘要： Described herein are methods for selecting cancer patients for treatment with a combination therapy comprising entinostat and a second therapeutic agent. In particular, methods are provided for the examination of a non-cancer cell type, myeloid-derived suppressor cells, e.g., those which are CD14-positive and HLA-DR-(lo/negative), as a therapeutic indicator in the setting of entinostat combination therapies.
-
公开(公告)号：EP2751267A1
公开(公告)日：2014-07-09
申请号：EP12827061.8
申请日：2012-08-31
IPC分类号： C12N15/09
CPC分类号： A61K31/566 , A61K31/4196 , A61K31/4406 , A61K31/5685 , A61K45/06 , A61P35/00 , G01N33/4833 , G01N2800/52 , A61K2300/00
摘要： Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
-
公开(公告)号：EP3381454A1
公开(公告)日：2018-10-03
申请号：EP18152916.5
申请日：2012-08-31
IPC分类号： A61K31/4196 , A61K31/4406 , A61K31/5685 , A61K45/06 , C12N15/09 , A61P35/00
CPC分类号： A61K31/566 , A61K31/4196 , A61K31/4406 , A61K31/5685 , A61K45/06 , A61P35/00 , G01N33/4833 , G01N2800/52 , A61K2300/00
摘要： Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of resistant, metastatic breast cancer with a combination of entinostat and an aromatase inhibitor.
-
10.发明公开COMBINATION OF HDAC INHIBITOR AND ANTI-PD-L1 ANTIBODY FOR TREATMENT OF CANCER 审中-公开HDAC抑制剂与抗PD-L1抗体治疗癌症的联合应用
公开(公告)号：EP3313433A1
公开(公告)日：2018-05-02
申请号：EP16818627.8
申请日：2016-06-28
IPC分类号： A61K39/00 , A61K35/12 , A61K39/395 , A61P43/00
CPC分类号： A61K39/3955 , A61K9/0019 , A61K31/4406 , A61K39/39558 , A61K2039/505 , A61K2039/545 , A61K2039/55 , A61P35/00 , C07K16/2827 , C07K2317/76 , C12Q1/6886 , G01N33/57415 , G01N2333/70596 , G01N2800/52 , A61K2300/00
摘要： Described herein are methods for the treatment of breast cancer in a subject. In particular, methods are provided for the treatment of metastatic triple negative breast cancer with a combination of entinostat and an anti-PD-L1 antibody, such as MPDL3280A.
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.011 秒)
